Information Provided By: 
Fly News Breaks for September 12, 2019
GMAB
Sep 12, 2019 | 06:26 EDT
JPMorgan analyst James Quigley upgraded Genmab to Overweight from Neutral with a price target of 1,500 kroner, up from 1,275 kroner. The analyst sees a positive risk/reward at current share levels as he believes the company's pipeline is supported by the "strong" Darzalex base business. Genmab's three key pipeline assets over 50% upside potential and only 13% downside risk, which could start to be realized with data readouts in December 2019 into the first half of 2020, Quigley tells investors in a research note.
News For GMAB From the Last 2 Days
There are no results for your query GMAB
